Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021058967 - COMBINATION OF GOLD COMPLEXES WITH OLAPARIB OR OTHER PARP1/2 INHIBITORS FOR USE IN THE TREATMENT OF CANCER RESISTANT TO SAID PARP1/2 INHIBITORS

Publication Number WO/2021/058967
Publication Date 01.04.2021
International Application No. PCT/GB2020/052322
International Filing Date 24.09.2020
IPC
A61K 31/28 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
28Compounds containing heavy metals
A61K 31/502 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
50Pyridazines; Hydrogenated pyridazines
502ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 45/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 31/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
28Compounds containing heavy metals
A61K 31/502
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
50Pyridazines; Hydrogenated pyridazines
502ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • VARSITY PHARMACEUTICALS LIMITED [GB]/[GB]
Inventors
  • HARRISON, James
  • DUER, Melinda
  • BASHTANOVA, Uliana
Agents
  • PETTY, Catrin
Priority Data
1913957.527.09.2019GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMBINATION OF GOLD COMPLEXES WITH OLAPARIB OR OTHER PARP1/2 INHIBITORS FOR USE IN THE TREATMENT OF CANCER RESISTANT TO SAID PARP1/2 INHIBITORS
(FR) COMBINAISON DE COMPLEXES D'OR AVEC DE L'OLAPARIB OU D'AUTRES INHIBITEURS DE PARP1/2 POUR UNE UTILISATION DANS LE TRAITEMENT DU CANCER RÉSISTANT AUXDITS INHIBITEURS DE PARP1/2
Abstract
(EN)
The present application is concerned with gold complexes for use in treating cancer which is resistant to a known therapy. In some embodiments, the cancer is resistant to a first PARP inhibitor and/or the gold complex is for use in combination with a second PARP inhibitor.
(FR)
La présente invention concerne des complexes d'or destinés à être utilisés dans le traitement du cancer qui est résistant à une thérapie connue. Dans certains modes de réalisation, le cancer est résistant à un premier inhibiteur de PARP et/ou le complexe d'or est destiné à être utilisé en combinaison avec un second inhibiteur de PARP.
Latest bibliographic data on file with the International Bureau